A New Cell Therapy Trial for MF

[EPguy]

Not sure if this has come up before.

This company is focused on improving SCT for bone cancers with a new agent, Orca-T.

orcabio.com/clinical-programs/

A phase 2 trial for MF had this result among others:

"Regression of marrow fibrosis to MF grade 0 or 1 was noted by D+ 100 in 7 of 7 Orca-T recipients but only in 1 of 6 SOC patients."

sciencedirect.com/science/a...

100% of (small sample) is neat. Other MF results were also promising.

They are also working on AML, although MPN related AML is unique. But maybe any AML can benefit:

For mostly AML: "The rate of chronic GVHD at 1 year was 5%... vs 38% ..." That is a big advantage.

--

Here is the ph3 clinical trial that includes AML, not clear whether MPN emergent AML is included:

clinicaltrials.gov/ct2/show...

--

They have a newer therapy, Orca-Q, that may allow less matched donors.

[EmeraldA]

Thank you for posting.

[CanadaG]

These are incredible results in their initial trials. There was actually a Wall Street Journal article about this company last weekend but no mention of SCT for MF. This looks like a very promosing therapy to improve SCT outcomes and post-transplant quality of life. Thank you so much for posting this

[EPguy in reply to CanadaG]

It was the WSJ article that got me looking deeper. It is potentially very good news for SCT, it would open it to more pts.

[CanadaG in reply to EPguy]

yes very good news indeed. Orca-T is already in Phase 3 for other forms of leukemia and the results look very promising thus far